EU expands use of Janssen’s Darzalex
admin 2nd May 2017 Uncategorised 0EU regulators have expanded the scope of Janssen’s Darzalex to include patients with multiple myeloma who have received at least one prior therapy, when given in combination with lenalidomide and dexamethasone, or bortezomib (Velcade).
More: EU expands use of Janssen’s Darzalex
Source: News